JPWO2020041340A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020041340A5 JPWO2020041340A5 JP2021510070A JP2021510070A JPWO2020041340A5 JP WO2020041340 A5 JPWO2020041340 A5 JP WO2020041340A5 JP 2021510070 A JP2021510070 A JP 2021510070A JP 2021510070 A JP2021510070 A JP 2021510070A JP WO2020041340 A5 JPWO2020041340 A5 JP WO2020041340A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- improvement
- composition according
- individual
- reduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 210000001747 pupil Anatomy 0.000 claims 19
- 230000004304 visual acuity Effects 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 10
- 239000007943 implant Substances 0.000 claims 6
- 230000000007 visual effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 2
- 241000284156 Clerodendrum quadriloculare Species 0.000 claims 2
- 229960003679 brimonidine Drugs 0.000 claims 2
- 230000004438 eyesight Effects 0.000 claims 2
- 230000004313 glare Effects 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004297 night vision Effects 0.000 claims 2
- 239000000049 pigment Substances 0.000 claims 2
- 201000010041 presbyopia Diseases 0.000 claims 2
- 210000002159 anterior chamber Anatomy 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 230000004350 nocturnal myopia Effects 0.000 claims 1
- 230000001179 pupillary effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720671P | 2018-08-21 | 2018-08-21 | |
| US62/720,671 | 2018-08-21 | ||
| PCT/US2019/047305 WO2020041340A1 (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534217A JP2021534217A (ja) | 2021-12-09 |
| JPWO2020041340A5 true JPWO2020041340A5 (https=) | 2022-08-26 |
| JP2021534217A5 JP2021534217A5 (https=) | 2022-08-26 |
Family
ID=67841225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510070A Pending JP2021534217A (ja) | 2018-08-21 | 2019-08-20 | 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20210205273A1 (https=) |
| EP (1) | EP3840750A1 (https=) |
| JP (1) | JP2021534217A (https=) |
| KR (1) | KR20210047323A (https=) |
| CN (1) | CN112823003A (https=) |
| AR (1) | AR115991A1 (https=) |
| AU (1) | AU2019325486A1 (https=) |
| BR (1) | BR112021003295A2 (https=) |
| CA (1) | CA3110318A1 (https=) |
| CL (1) | CL2021000440A1 (https=) |
| CO (1) | CO2021003460A2 (https=) |
| IL (1) | IL280990A (https=) |
| MX (1) | MX2021002112A (https=) |
| PH (1) | PH12021550372A1 (https=) |
| SG (1) | SG11202101730SA (https=) |
| TW (1) | TW202021584A (https=) |
| WO (1) | WO2020041340A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023514732A (ja) * | 2020-02-20 | 2023-04-07 | アラーガン、インコーポレイテッド | アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 |
| US12023276B2 (en) | 2021-02-24 | 2024-07-02 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
| AU2024217271A1 (en) * | 2023-02-08 | 2025-09-18 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| EP3085358B1 (en) | 2010-01-22 | 2017-11-01 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| WO2012149381A1 (en) * | 2011-04-28 | 2012-11-01 | Alpha Synergy Development, Inc. | Compositions and methods for improving night vision |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| WO2014143754A2 (en) | 2013-03-15 | 2014-09-18 | Allergan, Inc. | Prostamide-containing intraocular implant |
| JP2016515583A (ja) | 2013-03-27 | 2016-05-30 | フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． | オキュラー・インサートおよびその使用方法 |
| ES2834964T3 (es) | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| CN103338483B (zh) * | 2013-07-24 | 2016-08-10 | 成都西加云杉科技有限公司 | 数据分流方法、数据分流设备及异构网络 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| US11077053B2 (en) * | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
-
2019
- 2019-08-20 AU AU2019325486A patent/AU2019325486A1/en not_active Abandoned
- 2019-08-20 WO PCT/US2019/047305 patent/WO2020041340A1/en not_active Ceased
- 2019-08-20 TW TW108129699A patent/TW202021584A/zh unknown
- 2019-08-20 CN CN201980065608.3A patent/CN112823003A/zh active Pending
- 2019-08-20 KR KR1020217008132A patent/KR20210047323A/ko not_active Withdrawn
- 2019-08-20 MX MX2021002112A patent/MX2021002112A/es unknown
- 2019-08-20 JP JP2021510070A patent/JP2021534217A/ja active Pending
- 2019-08-20 US US17/055,922 patent/US20210205273A1/en not_active Abandoned
- 2019-08-20 EP EP19762588.2A patent/EP3840750A1/en not_active Withdrawn
- 2019-08-20 BR BR112021003295-9A patent/BR112021003295A2/pt not_active IP Right Cessation
- 2019-08-20 SG SG11202101730SA patent/SG11202101730SA/en unknown
- 2019-08-20 CA CA3110318A patent/CA3110318A1/en active Pending
- 2019-08-21 AR ARP190102374A patent/AR115991A1/es not_active Application Discontinuation
-
2021
- 2021-02-21 IL IL280990A patent/IL280990A/en unknown
- 2021-02-22 CL CL2021000440A patent/CL2021000440A1/es unknown
- 2021-02-22 PH PH12021550372A patent/PH12021550372A1/en unknown
- 2021-03-17 CO CONC2021/0003460A patent/CO2021003460A2/es unknown
- 2021-06-30 US US17/364,470 patent/US20220160623A1/en not_active Abandoned
- 2021-10-29 US US17/452,963 patent/US20220288031A1/en not_active Abandoned
-
2024
- 2024-03-08 US US18/599,800 patent/US20240358682A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI361701B (en) | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye | |
| US6273092B1 (en) | Methods for treating various eye disorders | |
| CA2672985C (en) | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia | |
| EP3031457B1 (en) | Medicament comprising pilocarpine and brimonidine | |
| JP2023105147A5 (https=) | ||
| Sawusch et al. | Use of collagen corneal shields in the treatment of bacterial keratitis | |
| JP2017061467A5 (https=) | ||
| JP2019524826A5 (https=) | ||
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| US6730691B1 (en) | Uses of alpha adrenergic blocking agents | |
| JP2021534217A5 (https=) | ||
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| RU2014151992A (ru) | Лечение воспалительных заболеваний глаз с применением лахинимода | |
| JPWO2020041340A5 (https=) | ||
| Alwitry et al. | Severe decompression retinopathy after medical treatment of acute primary angle closure | |
| CN116785290B (zh) | 苯环喹溴铵及其异构体在制备眼用制剂中的应用 | |
| Kang et al. | Phacoemulsification and posterior chamber intraocular lens implantation in uveitis. | |
| TW202317132A (zh) | 眼用組合物及/或用於老花眼、瞳孔放大及/或眼部不適管理之方法 | |
| JPWO2021168349A5 (https=) | ||
| US20260083730A1 (en) | Methods of treating eye disorders | |
| Snyder et al. | Hypopyon iridocyclitis associated with extended-wear soft contact lenses | |
| WO2003086465A1 (fr) | Medicament pour la chirurgie correctrice de la myopie | |
| RU2021106014A (ru) | Применение агонистов альфа-2-адренергических рецепторов для улучшения зрения | |
| Apel | A child with itchy eyes | |
| CA3217868A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin |